Filtered By:
Condition: Anaphylactic Shock
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 158 results found since Jan 2013.
Innovations in the Treatment of Anaphylaxis: A Review of Recent Data
Ann Allergy Asthma Immunol. 2023 Jun 4:S1081-1206(23)00404-0. doi: 10.1016/j.anai.2023.05.033. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: The current standard of first-line emergency treatment of anaphylaxis is intramuscular (IM) epinephrine administered most commonly via epinephrine autoinjector (EAI) in the outpatient setting. However, undercarriage and underuse of EAIs are common, and delayed epinephrine use is associated with increased morbidity and mortality. Patients, caregivers, and healthcare professionals have expressed a strong desire for small, needle-free devices and products that would offer improved car...
Source: Annals of Allergy, Asthma and Immunology - June 6, 2023 Category: Allergy & Immunology Authors: Jay A Lieberman John Oppenheimer Vivian P Hernandez-Trujillo Michael S Blaiss Source Type: research
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season
This report updates the 2020-21 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2020;69[No. RR-8]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. ACIP makes no preferential recommendation for a specific vaccine when more than one licensed, recommended, and age-appropriate vaccine is available. During the 2021-22 influenza season, the following types of vaccines are...
Source: MMWR Recomm Rep - August 27, 2021 Category: Epidemiology Authors: Lisa A Grohskopf Elif Alyanak Jill M Ferdinands Karen R Broder Lenee H Blanton H Keipp Talbot Alicia M Fry Source Type: research
